Research reportMultivariate analysis of bipolar mania: Retrospectively assessed structure of bipolar I manic and mixed episodes in randomized clinical trial participants
Introduction
Bipolar disorder has a complex presentation where episodes of affective dysregulation recur over time. While depressive and manic episodes have been described for centuries, there is still surprisingly little consensus over the structure of an episode of bipolar disorder. What are the essential building blocks of an episode and how can they combine?
While episodes of bipolar disorder are considered to be depressive or manic (hence ‘bipolar’), it has long been recognized that components of depressive and manic states can combine to produce so-called mixed states. Definitions of mixed states are controversial:
- (1)
It is not established whether depression is a dimensional characteristic of manic episodes, or whether mixed states are a distinct category of depressive-manic episodes.
- (2)
Mixed states may themselves be heterogeneous, with different forms having different clinical features and outcomes.
- (3)
Both the Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition (DSM-IV) and the International Statistical Classification of Diseases and Related Health Problems – Tenth Revision (ICD-10) diagnostic criteria used a categoric approach for mixed mania that essentially requires presence of full syndromal depression and mania; it has been suggested that this is too restrictive, and that meaningful clinical features emerge at subsyndromal levels of depressive symptoms (Swann et al., 2009).
- (4)
Mixed states or mixed characteristics could be validated by establishing relationships to response to treatments, course of illness or other clinical characteristics (Swann et al., 2002).
The symptomatic structure of manic episodes has been explored by applying multivariate statistics to symptom rating scales (Azorin et al., 2008, Bertschy et al., 2007, Cassidy et al., 1998, Dilsaver et al., 1999, Harvey et al., 2008, Lipkovich et al., 2008, Rossi et al., 2001, Sato et al., 2002, Swann et al., 2001). These studies have confirmed the heterogeneity of manic and mixed episodes, but had limitations (Cassidy et al., 1998, Dilsaver et al., 1999, Rossi et al., 2001, Sato et al., 2002), including relatively small samples and non-standardized symptom measures. Better understanding of the clinical structure of manic episodes would be useful in predicting treatment response and clinical course of illness, and in answering basic questions about episodes of bipolar disorder. Perhaps most important among these is whether there is a common basic structure underlying the apparent heterogeneity of bipolar episodes.
Using a large database from clinical trials in manic and mixed episodes (El Mallakh et al., 2010, Keck et al., 2003, Keck et al., 2009, Sachs et al., 2006, Vieta et al., 2005, Young et al., 2009), we have investigated the structure of manic and mixed episodes.
We conducted a factor/cluster analysis of Young Mania Rating Scale (YMRS) and Montgomery–Åsberg Depression Rating Scale (MADRS) line item scores from a pooled population of patients with manic or mixed episodes of bipolar I disorder enrolled in six clinical trials with aripiprazole in order to:
- •
identify the factor structure of psychiatric symptoms of the patients included in these studies;
- •
determine whether there are distinct clusters of episode types based on these factors;
- •
determine whether the same factor structure exists for episodes classified as being mixed or non-mixed for the sample as a whole.
Section snippets
Subjects
Factor analysis was performed on pooled data from patients with manic or mixed episodes of bipolar I disorder enrolled in six double-blind, randomized, controlled clinical trials with aripiprazole: CN138-007 (Sachs et al., 2006), CN138-008 (Vieta et al., 2005), CN138-009 (Keck et al., 2003), CN138-074 (El Mallakh et al., 2010), CN138-135 (Keck et al., 2009) and CN138-162 (Young et al., 2009). The studies were approved by the relevant Institutional Review Boards of their sites. All subjects were
Factor analysis of YMRS and MADRS item scores
Results of factor analyses, using the YMRS and MADRS line items across all subjects, are summarized in Table 2. The table shows the results of the primary factor analysis, carried out in all subjects, compared with separate analyses limited to mixed or non-mixed subjects. The results were essentially identical across groups. There were five factors with eigenvalues >1, accounting for over 50% of the total variance. Interestingly, the depression factor had the highest eigenvalue. The depression
Discussion
This analysis of data from 2179 patients with manic or mixed episodes associated with bipolar I disorder, enrolled in six double-blind, randomized, controlled clinical trials generated five major symptom factors. These factors, and the derived clusters, resembled those found in other, generally smaller studies, as summarized in Table 5. It is important to keep in mind that detailed results of factor analyses will depend on the nature of the clinical sample and on the variables going into the
Conclusions
In a large pretreatment sample of clinical trial participants meeting DSM-IV criteria for manic or mixed episodes, factor and cluster analysis revealed a similar structure across all patients and those characterized as mixed or non-mixed. Depression was the dominant factor, accounting for most of the variance. Cluster analysis showed that patients with high depression factor scores were heterogeneous with respect to irritability. Poor impulse control and irritability were essentially constant
Role of funding source
The studies analyzed in this manuscript were supported by Bristol-Myers Squibb Company and Otsuka Pharmaceutical Company, Ltd.
Conflict of interest
Alan C. Swann has been a Consultant for Bristol-Myers Squibb, Merck and Pfizer. He has also been a Speaker for Abbott, Merck and Sanofi Aventis.
Trisha Suppes has received funding or medications for clinical grants from Abbott Laboratories, AstraZeneca, GlaxoSmithKline Pharmaceuticals, Janssen Pharmaceuticals, JDS Pharmaceuticals, LLC, National Institute of Mental Health, Novartis Pharmaceuticals, Pfizer, Inc., Solvay Pharmaceuticals and Wyeth Pharmaceuticals (shown combined as this was a
Acknowledgments
Editorial assistance was provided by Ogilvy Healthworld, which was supported by Bristol-Myers Squibb Company and Otsuka Pharmaceutical Company, Ltd.
References (23)
- et al.
A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007)
European Neuropsychopharmacol
(2010) - et al.
Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study
Journal of Affective Disorders
(2009) - et al.
A factor analysis of signs and symptoms of the manic episode with Bech–Rafaelsen Mania and Melancholia Scales
Journal of Affective Disorders
(2001) - et al.
Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania
Neuropsychopharmacology
(2002) - et al.
Structure of mania: depressive, irritable, and psychotic clusters with different retrospectively-assessed course patterns of illness in randomized clinical trial participants.
Journal of Affective Disorders
(2001) Diagnostic and Statistical Manual of Mental Disorders
(2000)- et al.
Toward the delineation of mania subtypes in the French National EPIMAN-II Mille Cohort. Comparisons with prior cluster analytic investigations
European Archives of Psychiatry and Clinical Neuroscience
(2008) - et al.
Phenomenology of mixed states: a principal component analysis study
Bipolar Disorders
(2007) - et al.
A factor analysis of the signs and symptoms of mania
Archives of General Psychiatry
(1998) - et al.
Phenomenology of mania: evidence for distinct depressed, dysphoric, and euphoric presentations
American Journal of Psychiatry
(1999)
The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment
Bipolar Disorders
Cited by (14)
Psychopathology of Mixed States
2020, Psychiatric Clinics of North AmericaCitation Excerpt :Euphoric mania entails elevated mood, increased self-esteem or grandiosity, and increased energy and activity,16,24,31 with little or no irritability/hostility,16 anxiety, or psychosis.24,31 Sleep disturbance may be present or not.16 The main characteristic is the relative (although not complete) absence of depressive symptoms.16,24
Evaluating response to mood stabilizers in patients with mixed depression: A study of agreement between three different mania rating scales and a depression rating scale
2016, Journal of Affective DisordersCitation Excerpt :It is possible that a patient could experience worsening in core depressive symptoms without a change in total depression score (Gonzalez-Pinto et al., 2003). For mixed depression, the identified factors of the mixed component include irritability/aggressiveness, flight of ideas/racing thoughts, psychomotor agitation, increased talkativeness, and distractibility (Swann et al., 2013b). On the other hand, common to mixed mania are anxiety, one depressive component, irritability/hostility, and one component of psychosis, as well as the classic elevation of mood and psychomotor activation symptoms of mania (Swann et al., 2013a,b).
Cannabis and Bipolar Manic Episodes
2016, Neuropathology of Drug Addictions and Substance MisuseCannabis and Bipolar Manic Episodes
2016, Neuropathology of Drug Addictions and Substance Misuse Volume 1: Foundations of Understanding, Tobacco, Alcohol, Cannabinoids and OpioidsPhenomenological subtypes of mania and their relationships with substance use disorders
2015, Journal of Affective DisordersClinical practice guideline on bipolar disorder: Drug and psychosocial therapy
2013, Medicina Clinica